Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of GVHD prophylaxis after unrelated donor nonmyeloablative peripheral blood stem cell transplantation
2005-003305-90Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus, sirolimus, mycophenolic acid and fludarabine in hematopoietic malignancies (3 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of acute grade II-IV graft-versus-host disease and Non-relapse mortality before day 200. Started Mar 2006; status: completed.
02
Drugs
tacrolimussirolimusmycophenolic acidfludarabine
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2005-003305-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003305-90.